A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems

What Was Tested

The trial (phase 3) is built around Orforglipron (Foundayo, non-peptide).

Participation in this study will last about 53 weeks (about 1 year).

It had two arms (groups): Orforglipron (experimental) and Placebo (placebo comparator).

Participants will receive orforglipron orally.

Participants will receive placebo orally.

The registry classes the interventions as drug.

Who Took Part

192 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Obstructive sleep apnea. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.

The full record lists 7 inclusion and 4 exclusion criteria; among the exclusions: have type 1 diabetes (t1d), type 2 diabetes (t2d), or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma; have a self-reported change in body weight \>5 kg within 90 days prior to screening; had chronic or acute pancreatitis any time prior to screening.

How the Study Was Run

It was run as a randomized, parallel-group and double-blind study.

The participants were allocated by chance, so the Orforglipron (Foundayo, non-peptide) group and the comparison group should start out alike.

The Orforglipron (Foundayo, non-peptide) group and the comparison group ran side by side rather than switching.

Neither the participants nor the staff measuring them knew who was on Orforglipron (Foundayo, non-peptide), so expectations could not easily colour the readings.

Those kept unaware of assignments: participant and investigator.

It started in 2026-12 with completion listed for 2028-03.

It ran at 13 sites in China (13).

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Mean Percent Change From Baseline in Body Weight (time frame: Baseline, Week 48).

It also tracked 10 secondary outcomes, for example Mean Change from Baseline in Waist Circumference, Mean Change from Baseline in Body Mass Index (BMI), Mean Change from Baseline in Hemoglobin A1c (HbA1c), Mean Change from Baseline in Fasting Glucose, Mean Percent Change from Baseline in Fasting Insulin and Mean Change from Baseline in Systolic Blood Pressure (SBP).

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Orforglipron (Foundayo, non-peptide) in 192 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Orforglipron (Foundayo, non-peptide) compound page, all human trials.